Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers

Antill, YC; Mitchell, G; Johnson, SA; Devereux, L; Milner, A; Di Iuiio, J; Lindeman, GJ; Kirk, J; Phillips, KA; Campbell, IG

Author(s): Antill, YC; Mitchell, G; Johnson, SA; Devereux, L; Milner, A; Di Iuiio, J; Lindeman, GJ; Kirk, J; Phillips, KA; Campbell, IG;
Details: Publication Year 2010-01,Volume 19,Issue #1,Page 265-274
Journal Title: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Publication Type: Journal Article
Abstract: Purpose: Genomic alterations (including gene hypermethylation) are likely to precede the phenotypic changes associated with breast tumorigenesis. From a prospective collection Of ductal lavage (DL) samples from women with a known mutation in BRCA1 or BRCA2, we have assessed promoter methylation with a comparison of results with several variables, including breast cancer (BC) Outcome. Experimental Design: Hypermethylation of p16, RASSF1A, twist, and RAR beta was assessed using a qualitative, real-time, nested PCR assay. Associations between methylation status and variables were tested using Fisher's exact test or logistic regression. Analyses were done at three levels: a single breast, a single duct (both over time), and each DL sample in isolation. Results: A total of 168 samples from 93 ducts in 54 breasts have been analyzed in 34 women (16 BRCA1 and 18 BRCA2 mutation carriers). A median of 2 DL was done (range, 1-5), with 7 women developing BC on study, I bilateral. Methylation of p16 was associated with a known BRCA1 mutation (P = 0.001, P < 0.001, and P < 0.001 for breast, duct, and sample levels, respectively) and women with a history of contralateral BC (P 0.001 and P < 0.001 for duct and sample levels, respectively). An association was seen for women who developed BC on study and RASSF1A methylation (P = 0.001 for sample level). Conclusions: Genetic methylation patterns could potentially be used to predict future BC risk. In addition, p16 methylation may be a predictor of BRCA1 mutation status. Further research is required to corroborate these findings. Cancer Epidemiol Biomarkers Prev: 19(1): 265-74. (C)2010 AACR.
Publisher: AMER ASSOC CANCER RESEARCH
Keywords: ABERRANT PROMOTER METHYLATION; TUMOR-SUPPRESSOR GENE; RISK-REDUCING SURGERY; DNA METHYLATION; CANCER-PATIENTS; EXPRESSION PROFILES; OVARIAN-CANCER; LAVAGE FLUID; HYPERMETHYLATION; SERUM
Publisher's Version: https://doi.org/10.1158/1055-9965.EPI-09-0359
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2010-01-01 12:00:00